Acerus Pharmaceuticals (ASP-T)

Good company. In some interesting spaces in terms of hormonal stuff. They are on the search for a Viagra for women. The numbers into 2016 are looking pretty good. He wants to see one or 2 more quarters, but if they keep doing things the way they are, it is a name he would be interested in. Wouldn’t be surprised if he ends up owning it in 2016.

Working on an application of testosterone. In the current method you have to be extremely careful using it. This is a nasal application. If successful, it will be beneficial. There seems to be a debate of testosterone supplementing for men, which seems to have died down a little. There will be a reasonable opportunity to get the results over the next 6 months. Lost $0.27 last year, which is improving to a loss of $0.11 this year. If they are successful, the stock could be quite significant. Very speculative.

(Market Call Minute.) Wouldn’t own this. Too risky and there are a lot of financing issues. High risk.

Have an ingenious nasal application system. Still waiting for the next stages of approval, particularly on the application for men. Application for women is behind that.

In the drug delivery systems business. Good management. Into phase 3. Part of the problem recently is that one of the big investors has been selling, which has spooked some people.